Annual Meeting of the Association for Health Services Research. Washington, DC, USA, 1998/06/21.
To analyze the net benefit and cost-effectiveness of methotrexate use and Goeckerman therapy for psoriasis.
Net benefit and cost-effectiveness depend on the costs, efficacy, and utilities of therapy.
Utilities are quantitative measures of patient preferences.
We obtained costs by using resource-based accounting techniques.
Efficacy was estimated from literature reports.
We surveyed patients with psoriasis, dermatologists, and healthy subjects using utility assessment methods.
All assumptions were examined in a sensitivity analysis.
For net benefit, if benefits outweighed the costs, it was deemed worth providing.
For the cost-effectiveness analysis, the ratio of costs-to-effectiveness of less than $35 000 was considered cost-effective.
Using utilities from healthy nonexperts, the costs of both therapies exceeded the benefits in mild and moderate psoriasis.
In severe psoriasis, only methotrexate demonstrates a net benefit.
Both therapies were cost-effective compared with no therapy.
Liquid methotrexate should be chosen over the tablet form since it was cheaper and had the same outcome.
Goeckerman was cost-effective against liquid methotrexate in severe, but not mild or moderate psoriasis.
There was a trend for therapies to be more cost-effective when using patient utilities and less with dermatologist utilities.
The results were highly sensitive to efficacy and utilities. (...)
Mots-clés Pascal : Psoriasis, Traitement, Analyse avantage coût, Analyse coût efficacité, Chimiothérapie, Méthotrexate, Etude comparative, Goudron, Dithranol, Antipsoriasique, Voie locale, Voie percutanée, Etude statistique, Etats Unis, Amérique du Nord, Amérique, Economie santé, Homme, Peau pathologie
Mots-clés Pascal anglais : Psoriasis, Treatment, Cost benefit analysis, Cost efficiency analysis, Chemotherapy, Methotrexate, Comparative study, Tar, Dithranol, Antipsoriatic agent, Local administration, Percutaneous route, Statistical study, United States, North America, America, Health economy, Human, Skin disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0074046
Code Inist : 002B08D. Création : 31/05/1999.